

Global Access Program



Providing innovative diagnostics solutions to those **who need it most**



Universal access to quality healthcare and medical innovation remains a global challenge.

As a community we have an ambitious goal: to stop as many diseases as possible.

Roche continues to partner with national governments, local healthcare facilities, communities and international agencies to go beyond providing diagnostics tests.



The Roche Global Access Program provides access to diagnostics for HIV, hepatitis, tuberculosis, cervical cancer, and COVID-19 in high disease burden and qualified countries where reliable diagnostic solutions are needed most.



Global Access Program
take aim at HIV


Global Access Program
take aim at hepatitis

Global Access Program
take aim at tuberculosis


Global Access Program
take aim at cervical cancer

Global Access Program
take aim at COVID-19

Global Access Program Timeline



Disease Prevalence: Deaths



HIV

In 2022, approximately **630,000** people died due to HIV.¹

Hep

In 2022, hepatitis B resulted in an estimated **1.1 million** deaths.² In 2022, approximately **242,000** people died from hepatitis C.³

TB

In 2022, **1.3 million** died from the disease.⁴

HPV

In 2022, more than **350,000** women died of cervical cancer, more than 94% of these deaths occurring in low- and middle-income countries.⁵

COVID-19

In 2020, COVID-19 caused more than **1.8 million** deaths globally.¹⁰

Disease Elimination Goals

HIV goals by 2030⁶

95%

of people living with HIV will know their HIV status

95%

of people who know their status receive treatment

95%

of treatment on HIV treatment have a suppressed viral load

Hepatitis goals by 2030⁷

90%

reduction in new cases of chronic hepatitis B and C

65%

reduction in hepatitis B and C

80%

of treatment eligible persons with chronic hepatitis B and C infections

TB goals by 2030⁸

90%

reduction in the absolute number of TB deaths

80%

reduction in the TB incidence rate

0%

of TB-affected households experiencing catastrophic costs due to TB

Cervical cancer goals by 2030⁹

90%

of girls fully vaccinated with HPV vaccine by 15 years of age


70%

of women HPV screened at 35 and 45 years of age and all managed appropriately


90%

of women identified with cervical disease receive treatment for precancerous lesions or invasive cancer


COVID-19 Elimination Strategy⁸



Increase diagnostic testing for disease surveillance and to prevent initial spread



implement physical distancing measures to decrease rates of transmission



increase awareness, education, and access to vaccinations

Countries with Global Access Program

The program provides increased access to diagnostics at affordable pricing for qualifying organizations in 82 eligible countries with the highest disease burden.



References:

1. <https://www.who.int/news-room/fact-sheets/detail/hiv-aids> (accessed on May 30, 2024)
 2. <https://www.who.int/news-room/fact-sheets/detail/hepatitis-b> (accessed on May 30, 2024)
 3. <https://www.who.int/news-room/fact-sheets/detail/hepatitis-c> (accessed on May 30, 2024)
 4. <https://www.who.int/news-room/fact-sheets/detail/tuberculosis> (accessed on May 30, 2024)
 5. <https://www.who.int/news-room/fact-sheets/detail/cervical-cancer> (accessed on May 30, 2024)
 6. Understanding Fast-Track. Accelerating Action to end the AIDS epidemic by 2030.
https://www.unaids.org/sites/default/files/media_asset/201506_JC2743_Understanding_FastTrack_en.pdf (Accessed 29 March 2021)
 7. <https://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-2016.06-eng.pdf;jsessionid=AC1645C173756FB7A161689347064065?sequence=1> (accessed 7 Nov 2019)
 8. The End TB Strategy 2022. Geneva: World Health Organization; 2022.
 9. <https://www.who.int/news-room/fact-sheets/detail/cervical-cancer> (accessed on May 30, 2024)
 10. <https://www.who.int/data/stories/the-true-death-toll-of-covid-19-estimating-global-excess-mortality>. Accessed 28 June 2021
 11. Baker MG, Willson N, Anglemeyer A. Successful Elimination of Covid-19 Transmission in New Zealand. N Engl J Med 2020;383:e56. 10.1056/NEJMc2025203